Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive crawled date : 2021 - 05 - 24 save search
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma
Published: 2021-05-24 (Crawled : 13:00) - biospace.com/
APM | $5.66 18K
|
Health Technology
|
| O: 9.75%
H: 35.53%
C: 7.2%
positive trial als staphylococcus aureus
BrainsWay Announces First of its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS™
Published: 2021-05-24 (Crawled : 12:15) - globenewswire.com
CNC | $76.3 0.95% 590K
|
Health Services
|
| O: 0.31%
H: 0.58%
C: -0.05%
BWAY | $4.89 2.95% 13K
|
Health Technology
|
| O: 12.93%
H: 2.5%
C: -2.11%
treatment positive
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
Published: 2021-05-24 (Crawled : 12:00) - biospace.com/
MRK | $126.99 0.04% 3.1M
|
Health Technology
|
| O: 0.44%
H: 0.15%
C: -0.63%
treatment positive therapy cancer chmp her2+ keytruda her2- her2
Iridium Makes Strategic Investment in DDK Positioning, Provider of Enhanced GNSS Accuracy Solutions
Published: 2021-05-24 (Crawled : 12:00) - prnewswire.com
IRDM | News | $28.51 1.42% 590K
|
Communications
|
| O: 0.87%
H: 0.91%
C: 0.08%
positive
Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021
Published: 2021-05-24 (Crawled : 12:00) - biospace.com/
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: 7.19%
H: 3.88%
C: -12.01%
presentation positive hepatitis
4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome
Published: 2021-05-24 (Crawled : 06:00) - 4dpharmaplc.com
LBPS | $1.65 -0.61%
|
Manufacturing
| Email alert
Add to watchlist
positive treatment positive results results syndros
Libtayo® (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
Published: 2021-05-24 (Crawled : 06:00) - prnewswire.com
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 0.02%
H: 0.3%
C: -0.3%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: -1.82%
treatment europe positive cancer chmp
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.